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Sharon J Peacock1,2* and George M Weinstock3Editorial summary
Recent advances in sequencing technologies are
changing the face of infectious disease investigation
and control. Personalized anti-infective therapies and
surveillance of emergent pathogen outbreaks are just
two examples of the potential benefits of merging the
fields of genomics and infectious diseases.tuberculosis (TB), sequencing technologies will be used toEditorial
This Genome Biology and Genome Medicine collabora-
tive special issue on the genomics of infectious diseases
is very timely. Vaccination, access to clean water, and
antimicrobial drugs have all changed the relationship
between humans and pathogens, resulting in a marked
increase in life expectancy. Yet, infectious diseases con-
tinue to take their toll on human health worldwide, and
events such as the recent Ebola outbreak in West Africa
serve as a sharp reminder of how fragile any success is
in the control of pathogens. A more insidious but perva-
sive threat to human health is the emergence and dissem-
ination of antimicrobial resistance among numerous
pathogens, paralleled by a decline in antimicrobial drug
discovery. Advances in sequencing technologies have
resulted in the availability of instruments that can be
operated in a clinical environment, together with high-
throughput platforms that can be used to define pathogens
at the population level. These technologies have numerous
potential applications for the control of infectious diseases.
Sequencing will bring improvements in the detection
and control of outbreaks associated with multidrug-
resistant and other pathogens in hospitals and the com-
munity [1]. Confirmation of an outbreak could lead to
earlier implementation of interventions that bring the out-
break to a close [2]. Conversely, excluding an outbreak* Correspondence: sjp97@medschl.cam.ac.uk
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creativecommons.org/publicdomain/zero/1.0/) awith confidence will reduce unnecessary infection control
interventions [3]. Pathogen sequencing will be used to
tailor individual patient prescribing. Capillary sequencing
of the human immunodeficiency virus (HIV) is already
used to guide the treatment of patients who are HIV posi-
tive, but newer sequencing technologies will bring the
added benefit of detecting resistant variants present as a
minority of the HIV population in a given individual. In
predict antimicrobial resistance of the causative agent,
Mycobacterium tuberculosis [4]. This will bring the
greatest benefit to patients with multidrug-resistant
and extensively drug-resistant TB (against which first- and
second-line drugs are not effective), because conventional
testing of second-line drugs is lengthy. Accurate prescrib-
ing could lead to more rapid resolution of infection and
reduced risk of onward transmission. Genome sequencing
also defines transmission of M. tuberculosis between indi-
viduals with greater resolution and certainty than was pre-
viously possible [5].
Passive surveillance using sequence data generated for
clinical use would provide an overview of the emergence
and spread of antimicrobial resistance. Active genomic
surveillance of key human pathogens would provide an
early warning system for outbreaks, inform vaccine strat-
egies through tracking of vaccine escape, and detect the
emergence of new clones that harbor known or novel
virulence determinants. Sequencing is being used to
identify reservoirs of antimicrobial-resistance genes in
hospitals, other healthcare facilities, the community, and
livestock farming, as well as common transmission path-
ways between them. Finding pinch-points to stop trans-
mission between reservoirs could limit the dissemination
of antimicrobial resistance. Sequencing also provides in-
sights into the emergence of infectious diseases. For ex-
ample, reconstruction of the early dynamics of the HIV
pandemic using sequence data and statistical approaches
identified Kinshasa in the 1920s as the focus of early
transmission and the source of pre-1960 pandemic vi-
ruses elsewhere [6]. Sequencing of the more recentlyioMed Central Ltd. The licensee has exclusive rights to distribute this article, in any
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and comparison of sequence data for isolates from humans
and dromedary camels has been cited as evidence for the
role of camels as a reservoir [7].
Sequencing also has a role in drug discovery pathways,
the laboratory evaluation of lead compounds, and the
clinical phases of drug evaluation. For example, in 2005,
in the first published use of 454 pyrosequencing, the F0
subunit of ATP synthase was identified as the target of
bedaquiline [8]. Bedaquiline subsequently became the
first representative of the only novel class of anti-TB
agents to be approved in 40 years. Sequencing of M. tu-
berculosis during clinical trials can be used to distinguish
exogenous re-infection from a relapse of the primary
infection, which is crucial to assess the efficacy of study
drugs. Sequencing technologies will also underpin clin-
ical trials evaluating the effect of a therapeutic alteration
of the microbiome in a range of conditions. The benefit
derived from duodenal infusion of donor feces in
patients with recurrent Clostridium difficile infection pro-
vides proof-of-principle for clinical utility [9]. Extending
this to other diseases will need to be supported by detailed
genomic analyses of the human microbiota, together with
a better understanding of the interactions between the na-
tive or medically altered microbiome and host immunity.
Several challenges remain before microbial sequencing
becomes routine for diagnostic and public health micro-
biology laboratories. A suite of software tools will be re-
quired to convert sequence data into a format that is
relevant and useful for clinicians and infection control
teams. New methods to handle and process ever-
expanding pathogen-specific microbial genome databases
will also be needed, including global and region-specific
listings of gene mutations associated with drug resistance.
It is also essential that existing mechanisms for the devel-
opment of standard operating procedures and accredit-
ation of laboratory methods be applied to microbial
sequencing. Working within a tightly controlled diagnostic
laboratory will reduce errors (for example, through sample
tracking) and allow data to be handled within an existing
framework that protects patient confidentiality.
Further technological advances are also required to re-
duce the turnaround time between taking a clinical sam-
ple and generating sequence data. Refinements such as
extracting DNA directly from a bacterial colony on a
culture plate can reduce the processing time by up to a
day [10]. However, the need to culture the sample to ob-
tain a pure growth of bacteria from which to purify
DNA prior to sequencing, rather than performing direct
sequencing on the sample, means that timelines are still
tied to bacteriology methods that were developed more
than a hundred years ago. Regardless, the enthusiasm
for direct sequencing of clinical samples should be tem-
pered by the probable reality of doing so. Most samplessent to a diagnostic laboratory are currently reported
out as ‘no growth’ or, through the use of selective culture
media that target specific pathogens, ‘no significant
growth’. In a brave new world where all samples are se-
quenced as the primary method for pathogen detection,
it may prove the case that the majority of samples will
be sequence-positive. Re-defining what data can be dis-
regarded and what might represent new and important
findings will take at least a generation of microbiologists
to resolve.
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